- 中国科技论文统计源期刊
- 中国科技核心期刊
| Citation: |
Li Jin-cong, Zhang Nan-hui, Wang Lei, Peng Jun-meng, Wang Hui-hui, Chen Wen-hui. Efficacy of angiotensin receptor neprilysin inhibitor for maintenance hemodialysis patients with different types of left ventricular ejection fraction heart failure[J]. Journal of Clinical Nephrology, 2024, 24(12): 1001-1009. DOI: 10.3969/j.issn.1671-2390.2024.12.005
|
To explore the therapeutic efficacy of sacubitril/valsartan （S/V）, a representative drug of angiotensin receptor enkephalinase inhibitors （ARNI）, in patients with different types of left ventricular ejection fraction （LVEF） heart failure （HF） on maintenance hemodialysis （MHD）.
From June 1, 2022 to May 31, 2023, 155 MHD patients with concurrent HF continuously taking S/V for more than 3 months were selected. According to the level of LVEF, they were assigned into three groups of HF with reduced ejection fraction（HFrEF, n=41）, HF with mid-range ejection fraction（HFmrEF, n=42） and HF with preserved ejection fraction（HFmrEF, n=2）. Heart rate （HR）, blood pressure （BP）, hemoglobin （Hb）, Potassium （K+）, uric acid （UA）, estimated glomerular filtration rate （eGFR）, creatinine （Cr）, brain natriuretic peptide （BNP） and echocardiographic findings before and after dosing were retrospectively reviewed.
After drug dosing, overall population HR [78.0（71.0, 89.0） beats/min vs 82.0（73.0, 95.0） beats/min], systolic blood pressure[138.0（123.0, 158.0） mmHg vs 155.0（139.0, 173.0） mmHg（1 mmHg=0.133 kPa）], diastolic blood pressure[78.0（68.0, 90.0） mmHg vs 90.0（76.0, 100.0） mmHg], BNP level[729.6（234.9, 1942.2） pg/ml vs 2562.7（928.9, 4957.1） pg/ml] and interventricular septal thickness[12.0（11.0, 13.0）mm vs 13.0（12.0, 14.0） mm] were lower than those pre-treatment（all P＜0.05）; LVEF was higher than pre-dosing [58.0（51.0. 61.0）% vs 49.0（40.0, 56.0）%]（P＜0.05）. The difference in proportional distribution of New York Heart Association （NYHA） cardiac function class before and after drug administration was statistically significant（P＜0.05）. In HFrEF group, heart rate[81.0（70.0, 100.0） beats/min vs 94.0（75.5, 110.0） beats/min], systolic blood pressure [130.0（118.0, 152.0）mmHg vs 146.0（128.0, 166.0） mmHg], diastolic blood pressure [80.0（63.5, 89.0）mmHg vs 79.0（72.0, 96.0）mmHg], BNP[1366.9（612.0, 2991.4） pg/ml vs 4294.9（2562.3, 5000.0） pg/ml] and ventricular septal thickness[12.0（11.0, 13.0）mm vs 13.0（11.0, 11.0, 14.0） mm] lower than pre-dosing （all P＜0.05）; LVEF was higher post-dosing than pre-dosing[48.0（42.5, 55.0）% vs 36.0（32.0, 39.0）%]（P＜0.05）. HFmrEF group had a higher post-dosing HR[75.0（68.8, 80.3）beats/min vs 80.5（75.0, 95.0）beats/min], systolic blood pressure[138.0（121.8, 159.0）mmHg vs 158.0（139.0, 181.3）mmHg], diastolic blood pressure[78.0（67.0, 91.3）mmHg vs 92.0（79.8, 104.8）mmHg], BNP[765.5（245.1, 2323.2）pg/ml vs 3179.7（1325.2, 4967.8）pg/ml] and interventricular septal thickness[12.0（11.0, 13.0）mm vs 13.0（12.0, 14.0）mm] declined as compared with pre-dosing （all P＜0.05）; LVEF was significantly higher after dosing[54.5（50.8, 60.0）% vs 47.0（44.0, 48.0）%]（P＜0.05）. In HFpEF group, systolic blood pressure[139.0（129.3, 161.0）mmHg vs 161.5（146.3, 173.8）mmHg], diastolic blood pressure[77.0（70.0, 91.0）mmHg vs 90.5（78.0, 99.8）mmHg], BNP[433.5（171.4, 1237.8）pg/ml vs 1109.0（651.9, 2772.5）pg/ml] and thickness of interventricular septum[12.0（11.0, 12.0）mm vs 13.0（12.0, 14.0）mm] were lower than pre-dosing （all P＜0.05）. LVEF rose obviously post-dosing [60.0（59.0, 65.0）% vs 56.0（54.0, 60.0）%]（P＜0.05）. The differences in K+, eGFR and UA levels before and after dosing were not statistically significant among HFrEF, HFmrEF and HFpEF groups （P＞0.05）.
S/V has been shown to lower HR, lower BR, improve HF, lessen septal hypertrophy and enhance myocardial contractility in MHD patients with different types of LVEF HF.
| [1] |
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2020,395(10225):709-733. DOI: 10.1016/S0140-6736(20)30045-3.
|
| [2] |
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease-a systematic review and meta-analysis[J/OL]. PLoS One,2016,11(7):e0158765. DOI: 10.1371/journal.pone.0158765.
|
| [3] |
Wang LM, Xu X, Zhang M, et al. Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance[J]. JAMA Intern Med,2023,183(4):298-310. DOI: 10.1001/jamainternmed.2022.6817.
|
| [4] |
Matsushita K, Ballew SH, Wang AYM, et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease[J]. Nat Rev Nephrol,2022,18(11):696-707. DOI: 10.1038/s41581-022-00616-6.
|
| [5] |
Cozzolino M, Galassi A, Pivari F, et al. The cardiovascular burden in end-stage renal disease[J]. Contrib Nephrol,2017,191:44-57. DOI: 10.1159/000479250.
|
| [6] |
Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes[J]. Nat Rev Nephrol,2022,18(6):378-395. DOI: 10.1038/s41581-022-00542-7.
|
| [7] |
Zhang R, Sun XT, Li Y, et al. The efficacy and safety of sacubitril/valsartan in heart failure patients: a review[J]. J Cardiovasc Pharmacol Ther, 2022, 27: 10742484211058681. DOI: 10.1177/10742484211058681.
|
| [8] |
刘卫华, 林紫宁, 洪富源. 血液透析并发心力衰竭的防治新进展[J]. 中国实用内科杂志,2021,41(11):917-921.DOI: 10.19538/j.nk2021110102.
Liu WH, Lin ZN, Hong FY. New progress in the prevention and treatment of heart failure in hemodialysis patients[J]. Chin J Practic Intern Med,2021,41(11):917-921. DOI: 10.19538/j.nk2021110102.
|
| [9] |
Katagiri M, Yamada S, Katoh M, et al. Heart failure pathogenesis elucidation and new treatment method development[J]. JMA J,2022,5(4):399-406. DOI: 10.31662/jmaj.2022-0106.
|
| [10] |
Toyoda S, Haruyama A, Inami S, et al. Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure[J]. J Cardiol,2020,75(2):140-147. DOI: 10.1016/j.jjcc.2019.07.011.
|
| [11] |
House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int,2019,95(6):1304-1317. DOI: 10.1016/j.kint.2019.02.022.
|
| [12] |
孙雪峰. 《中国透析患者慢性心力衰竭管理指南》解读[J]. 中国实用内科杂志,2023,43(3):210-217,230.DOI: 10.19538/j.nk2023030107.
Sun XF. Interpretation of Guidelines for the management of chronic heart failure in dialysis patients in China[J]. Chin J Practic Intern Med,2023,43(3):210-217,230. DOI: 10.19538/j.nk2023030107.
|
| [13] |
Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD[J]. J Am Soc Nephrol,2010,21(9):1550-1559. DOI: 10.1681/ASN.2009101047.
|
| [14] |
中华医学会肾脏病学分会, 中关村肾病血液净化创新联盟. 中国透析患者慢性心力衰竭管理指南[J]. 中华肾脏病杂志,2022,38(5):465-496.DOI: 10.3760/cma.j.cn441217-20210812-00068.
Chinese Society of Nephrology, Zhongguancun Nephrology&Blood Purification Innovation Alliance. Guidelines for the management of chronic heart failure in dialysis patients in China[J]. Chin J Nephrol,2022,38(5):465-496. DOI: 10.3760/cma.j.cn441217-20210812-00068.
|
| [15] |
Kido R, Akizawa T, Fukagawa M, et al. Interactive effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers or their combination on survival of hemodialysis patients[J]. Am J Nephrol,2017,46(6):439-447. DOI: 10.1159/000482013.
|
| [16] |
Zhang HY, Huetteman AT, Reyes EA, et al. Effects of sacubitril-valsartan in patients with various types of heart failure: a meta-analysis[J]. J Cardiovasc Pharmacol,2023,81(6):434-444. DOI: 10.1097/FJC.0000000000001421.
|
| [17] |
Ayalasomayajula S, Langenickel T, Pal P, et al. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor[J]. Clin Pharmacokinet,2017,56(12):1461-1478. DOI: 10.1007/s40262-017-0543-3.
|
| [18] |
Havakuk O, Elkayam U. Angiotensin receptor-neprilysin inhibition[J]. J Cardiovasc Pharmacol Ther,2017,22(4):356-364. DOI: 10.1177/1074248416683049.
|
| [19] |
Kuang H, Huang X, Zhou Z, et al. Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application[J]. Eur J Pharmacol,2021,907:174288. DOI: 10.1016/j.ejphar.2021.174288.
|
| [20] |
孙长丽, 董洋, 王丽姣, 等. 沙库巴曲缬沙坦治疗维持性血液透析合并心力衰竭的临床疗效[J]. 中华肾脏病杂志,2022,38(1):15-22.DOI: 10.3760/cma.j.cn441217-20210420-00003.
Sun CL, Dong Y, Wang LJ, et al. Clinical efficacy of angiotensin-receptor neprilysin inhibitors in the treatment of maintenance hemodialysis with heart failure[J]. Chin J Nephrol,2022,38(1):15-22. DOI: 10.3760/cma.j.cn441217-20210420-00003.
|
| [21] |
Lee S, Oh J, Kim H, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease[J]. ESC Heart Fail,2020,7(3):1125-1129. DOI: 10.1002/ehf2.12659.
|
| [22] |
Raphael DM, Liu Z, JIN Z, et al. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease[J]. Curr Med Res Opin,2021,37(7):1071-1078. DOI: 10.1080/03007995.2021.1908243.
|
| [23] |
赵新宇, 张力之, 刘莉. 沙库巴曲缬沙坦治疗维持性血液透析合并射血分数保留型心衰患者的临床疗效分析[J]. 医学研究杂志,2023,52(11):154-158,169.DOI: 10.11969/j.issn.1673-548X.2023.11.030.
Zhao XY, Zhang ZL, Liu L. Clinical efficacy of sacubitril/valsartan in the treatment of maintenance hemodialysis patients with heart failure with preserved ejection fraction[J]. Res J Med,2023,52(11):154-158,169. DOI: 10.11969/j.issn.1673-548X.2023.11.030.
|
| [24] |
Guo Y, Ren M, WanG T, et al. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF[J]. Front Cardiovasc Med,2022,9:955780. DOI: 10.3389/fcvm.2022.955780.
|
| [25] |
张聪, 郭艳红, 杨自君, 等. 沙库巴曲/缬沙坦在心力衰竭腹膜透析患者中的应用[J]. 肾脏病与透析肾移植杂志,2022,31(1):26-32.DOI: 10.3969/j.issn.1006-298X.2022.01.005.
Zhang C, Guo YH, Yang ZJ, et al. Sacubitril/valsartan in peritoneal dialysis patients with heart failure[J]. Chin J Nephrol Dial Transplant,2022,31(1):26-32. DOI: 10.3969/j.issn.1006-298X.2022.01.005.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
.png)
DownLoad: